## **High fidelity C-to-T editing with TALE base editors**

## Louisa Mayer<sup>1</sup>, Maria Feola<sup>1</sup>, Diane Tkach<sup>1</sup>, Aminah Lawal<sup>1</sup>, Sylvain Pulicani<sup>2</sup>, Robert Hong<sup>1</sup>, J Lomibao<sup>1</sup>, Alex Boyne<sup>1</sup>, Aymeric Duclert<sup>2</sup>, J Valton<sup>2</sup>, Philippe Duchateau<sup>2</sup>, Alexandre Juillerat<sup>1</sup>

<sup>1</sup> Cellectis Inc, New York, NY; <sup>2</sup> Cellectis SA, Paris, France

**TRAC TALEN®** 

CD52 TALEB

No TALEN®/

TALEB

## Abstract

TALE base editors (TALEB) are fusions of a transcription activator-like effector domain (TALE), split-DddA deaminase halves, and a uracil glycosylase inhibitor (UGI). The C-to-T class of TALEB edits double strand DNA by converting a cytosine (C) to a thymine (T) via the formation of a uracil intermediate. We recently developed and applied a strategy that allowed the comprehensive characterization of C-to-T conversion efficiencies within the target editing window. This method also takes advantage of a highly precise and efficient TALEN®-mediated knock-in of ssODN in primary T cells to assess how the composition and spacer variations of target sequences affect TALEB activity/efficiency. Additionally, we highlighted that the composition of bases surrounding the target bases (TC) may strongly influence the editing efficiencies. We also demonstrated that different TALEB scaffolds could be used to relax target sequence limitations (to increase the targetable sequence) or be used to decrease or eliminate bystander editing within the editing window (to increase specificity). Overall, these findings allow for the fine-tuning of TALEB for a desired gene editing outcome. We then applied a range of different techniques to assess characteristics of nuclear genome editing. First, we focused on on-target editing and then explored the possibility and risk associated with genome-wide TALE-dependent/independent binding and editing. By using an experimental model relevant for therapeutic application with TALEB mRNA vectorization in primary cells (e.g. PBMCs and HSCs), we demonstrated that targeted binding of a single TALEB arm does not lead to detectable editing (detection limit: 0.1-0.2%). Finally, we further applied hybrid capture assays to test for off-target editing, in particular, within regions of the genome that were previously highlighted in cell lines. We demonstrated, in our relevant experimental setup with primary T cells, that editing at these sites was not detectable (detection limit: 0.2%). Altogether, the results of this study have enhanced our control and use of TALEB and allow for the design of extremely efficient (high editing frequencies and edit purity) and specific (absence of TALE-independent off sites and very limited, if not absent, DSB generation) TALEB, compatible with the development of future therapeutic applications.



TALEB do not generate DSBs

01

No translocations were

detected between a bait

DSB (nuclease) and a TALEB

editing site. Translocations

**TRAC TALEN®** 

CD52 TALEN®

This communication expressly or implicitly contains certain forward-looking statements concerning Celectis is providing this communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information, future events or otherwise. This communication expressly or implicitly contains certain forward-looking statements contained herein as a result of new information, future events or otherwise. This communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information, future events or otherwise. This communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information, future events or otherwise. This communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information, future events or otherwise. This communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information. TALEN® and Celectis is providing this communication as of this date and does not undertake b update any forward-looking statements contained herein as a result of new information.